Attiva gli avvisi di lavoro via e-mail!
Aumenta le tue possibilità di ottenere un colloquio
Crea un curriculum personalizzato per un lavoro specifico per avere più probabilità di riuscita.
A leading pharmaceutical company in Italy is seeking a Senior Medical Writer to produce and edit essential clinical documents. The role involves ensuring regulatory compliance while coordinating various drafting responsibilities. Ideal candidates will have a strong background in medical writing and a commitment to high-quality standards, alongside a deep understanding of the oncology drug development process.
Senior Medical Writer (Clinical and Regulatory Medical Writing)
Location : Netherlands (remote)
Reports to Head of Medical Writing
As a Sr Medical Writer, you will be responsible for planning, writing, reviewing, editing, formatting, and finalising critical clinical documents such as study reports, protocols, investigator brochures, package inserts, and regulatory submissions. You will ensure that all documents adhere to regulatory standards and accurately reflect the scientific data, supporting our clinical development programs by providing clear and concise communication of scientific information.
If you are a skilled Medical Writer with a passion for scientific communication, we encourage you to apply!
Responsibilities
Qualifications
Drug Development Knowledge
Clinical Information and Strategy :
Technical Skills and Competencies :
The Company
Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Group’s headquarters are still located today. High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history.
Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of haematological and solid tumours. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarini’s oncology portfolio, adding both commercial and clinical-stage assets. Tagraxofusp is a novel, first in class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and to date, the only approved treatment for BPDCN in the U.S. and EU, and the first and only approved CD123-targeted therapy.
Menarini Stemline is an equal-opportunity employer. We celebrate diversity and are committed to creating an inclusive environment for all employees.
J-18808-Ljbffr
J-18808-Ljbffr
Medical Writer • Abruzzo, Chieti, Italia